Drug profile

The FDA adverse-event record for Balanced Electrolyte Solution

32 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Balanced Electrolyte Solution. See the species affected, top reactions, and outcomes below.

32
adverse-event reports
6.3%
death-coded share
Dog
most-reported species
11
Hypotension - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
32
Total Reports
2
Deaths Reported
6.3%
Death Rate

Active Ingredients

Balanced Electrolyte Solution

Administration Routes

IntravenousUnknownSubcutaneous

Species Affected

Dog 19
Cat 13

Most Affected Breeds

Domestic Shorthair 9
Retriever - Labrador 4
Boxer (German Boxer) 3
Pug 2
Siamese 2
Maltese 1
Domestic Longhair 1
Bulldog 1
Deutsche Dogge, Great Dane 1
Dachshund - Miniature 1

Most Reported Reactions

Hypotension 11
Bradycardia 7
Diarrhoea 6
Lethargy (see also Central nervous system depression in 'Neurological') 6
Monocytosis 6
Neutrophilia 6
Leucocytosis NOS 6
Thrombocytopenia 6
Hyperglycaemia 6
Sedation 5
Lethargy (see also Central nervous system depression in Neurological) 5
Dehydration 5

Outcome Breakdown

Recovered/Normal
19 (59.4%)
Outcome Unknown
10 (31.3%)
Euthanized
2 (6.3%)
Recovered with Sequela
1 (3.1%)

Balanced Electrolyte Solution Adverse Event Insights

32 reports name Balanced Electrolyte Solution; 2 recorded a death outcome (6.3% of reported events, not a population-level mortality rate). Active ingredient: Balanced Electrolyte Solution. Administration routes: Intravenous, Unknown, Subcutaneous.

By species: Dog (19 reports), Cat (13 reports). By breed: Domestic Shorthair (9), Retriever - Labrador (4), Boxer (German Boxer) (3).

Leading clinical signs: Hypotension (11), Bradycardia (7), Diarrhoea (6), Lethargy (see also Central nervous system depression in 'Neurological') (6). Outcome, 32 coded reports: Recovered/Normal leads at 59.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.